Kovack Advisors’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
Kovack Advisors's ARCT Position: Q3 2026 in Review
Kovack Advisors opened a new position in Arcturus Therapeutics (ARCT) in Q3 2026: 10,899 shares worth $144K. The stake represents 0.01% of the portfolio and ranks #1010 among its holdings. This is a return to the name: Kovack Advisors previously reported a position in ARCT as recently as Q4 2025.
Kovack Advisors first reported a position in ARCT in Q4 2025 and has held it in 2 quarters since. The position peaked at $282K in Q4 2025. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.
- Kovack Advisors held 10,899 shares of Arcturus Therapeutics worth $144K as of Q3 2026.
- Arcturus Therapeutics was a new Kovack Advisors position in Q3 2026.
- Arcturus Therapeutics made up 0.01% of Kovack Advisors's portfolio in Q3 2026, its #1010 holding.
- Kovack Advisors first reported a position in Arcturus Therapeutics in Q4 2025 and has held it in 2 quarters since.
- Kovack Advisors's Arcturus Therapeutics position peaked at $282K in Q4 2025.
- 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.
Based on Kovack Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.